ArrowHead Pharma (ARWR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec3

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

19:56

Dec2

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

13:18

Dec1

Arrowhead Pharmaceuticals Director Reports Sale of Company Common Stock

23:11

Arrowhead Pharmaceuticals to Participate in Multiple Medical Conferences in December 2025 and Present on RNAi Therapies

21:00

Arrowhead Pharmaceuticals to Attend Multiple Healthcare Conferences in December 2025 to Showcase Plozasiran Progress

21:00

Nov28

B. Riley Maintains Arrowhead Pharmaceuticals 'Strong Buy' Rating, Projects EPS at $6.48

13:27

Schedules & Filings

Schedules

Filings

Nov25

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 256.47 M, Net Income -23.75 M, EPS -0.1741

Aug7

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 27.77 M, Net Income -175.24 M, EPS -1.2603

May12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 542.71 M, Net Income 370.45 M, EPS 2.75

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change